Showing results (661-670 of 2,441) with videos related to

Sort By:
Pageof 245
Clinical and Translational Science|April 28, 2020
hIL-7-hyFc, A Long-Acting IL-7, Increased Absolute Lymphocyte Count in Healthy SubjectsSang Won Lee, Donghoon Choi, MinKyu Heo, et al.
Clinical and Translational Science|April 9, 2020
Quantification of Natural Growth of Two Strains of Mycobacterium Marinum for Translational Antituberculosis Drug DevelopmentRob C Van Wijk, Astrid M van der Sar, Elke H J Krekels, et al.
Clinical and Translational Science|April 9, 2020
A Single and Multiple Ascending Dose Study of Toll-Like Receptor 7 Agonist (RO7020531) in Chinese Healthy VolunteersAndrea Luk, Qiudi Jiang, Katerina Glavini, et al.
Clinical and Translational Science|October 27, 2019
Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy VolunteersAndreas Becker, Emily C Martin, David Y Mitchell, et al.
Clinical and Translational Science|October 24, 2019
Lack of Detection of the Analgesic Properties of PF-05089771, a Selective Nav 1.7 Inhibitor, Using a Battery of Pain Models in Healthy SubjectsPieter Siebenga, Guido van Amerongen, Justin L Hay, et al.
Clinical and Translational Science|October 26, 2019
Metabolomic Profiling to Identify Molecular Biomarkers of Cellular Response to Methotrexate In VitroRyan S Funk, Rakesh K Singh, Mara L Becker
Clinical and Translational Science|August 17, 2021
Population pharmacokinetics and exposure-response analyses of teduglutide in adult and pediatric patients with short bowel syndromeJean-Francois Marier, Claudia Jomphe, Thomas Peyret, et al.
Clinical and Translational Science|August 11, 2021
What men want: Results from a national survey on decision making for prostate cancer treatment and research participationNancy P Mendenhall, Sarah M Rausch Osian, Curtis M Bryant, et al.
Clinical and Translational Science|August 13, 2021
Investor initiatives program: Public-private partnerships to expedite commercialization for NCI-funded small business entrepreneursBrittany Connors, Xing-Jian Lou, Ashim Subedee, et al.
Clinical and Translational Science|August 26, 2021
Required dose of sugammadex or neostigmine for reversal of vecuronium-induced shallow residual neuromuscular block at a train-of-four ratio of 0.3Jing He, Huan He, Xing Li, et al.
Pageof 245